The Nobel prize in medicine has been awarded for 2019 -- that was about a month ago. I heard about the announcement within a day or so and all that I was able to process was that it was something about oxygen levels and perhaps something about HIF-alpha and that it was possibly related to cancer. It was quite vague so I went about my business.
It has only been in the last day or so that clarificaiton has emerged; Specifically that one of the three winners of this year's Medicine Nobel was a coauthor on a significant 3-BP paper (the pancreatic cancer one that used a beta-cyclodextrin formulation of 3-BP).The results using systemic cyclo-3-BP in pancreatic cancer in vivo were impressive.
We talked a great deal about this article on the thread over the last 5 years and our working guess is that Cage wants to brings this formulation to clinical trials. It is frustrating, though, that after all these years a better formulation likely could be devised, yet at some point people want to move something forward; it would probably take years more research to optimize the existing formulation.
The relationship between the Nobel and the article is very unclear, and it will not be made any more clear for about 50 years until the deliberations are released. Nonetheless, the ongoing thread speculation that 3-BP will feature prominently on the Nobel podium appears to have already occurred. Perhaps this is a subtle nod by the Nobel committee to 3-BP. It would obviously have been interesting to have watched a 3-BP market security respond to this news, though such a 3-BP proxy is yet unlisted.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300523/